Fruquintinib

Fruquintinib is a potent and highly selective inhibitor of VEGFR kinase (IC50’s: VEGFR1= 33 nM, VEGFR2 = 35 nM, VEGFR3 = 0.5 nM) .1 It potently inhibited VEGF/VEGFR signaling and cell proliferation in HUVECs and HLECs and prevented angiogenesis in vitro. Fruquintinib is currently is several clinical trials against metastatic colorectal cancer2 and nonsquamous non-small-cell lung cancer3.